Pharma & Human Health
-
-
Pharma & Human Health -
Pharma & Human Health -
Pharma & Human Health -
Pharma & Human Health
Editor’s Choice
Editor's Choice
Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic products (LBPs), today announced positive top-line results from the Phase 2 ADORED study (Allergic Disease Onset pREvention stuDy) of STMC-103H, its lead investigational oral microbial […]
Editor's Choice
The OMNIgene™•VAGINAL device – Optimized solutions for vaginal microbiome studies
The women’s health gap refers to disparities in health outcomes and the limited research into conditions that exclusively affect women or affect them differently from men. This gap stems from the historic exclusion of females […]
Editor's Choice
MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round. The round was led by […]
In Case you Missed it:
Editor's Choice
Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic products (LBPs), today announced positive top-line results from the Phase 2 ADORED study (Allergic Disease Onset pREvention stuDy) of STMC-103H, its lead investigational oral microbial […]
Editor's Choice
The OMNIgene™•VAGINAL device – Optimized solutions for vaginal microbiome studies
The women’s health gap refers to disparities in health outcomes and the limited research into conditions that exclusively affect women or affect them differently from men. This gap stems from the historic exclusion of females […]
Pharma & Human Health
Ferring Presents New Data Analyses for REBYOTA®
Ferring Pharmaceuticals shared an oral presentation last month detailing microbiome restoration from the Phase 3b CDI-SCOPE study among patients with recurrent C. difficile (C. diff) infection (CDI) who received REBYOTA® (fecal microbiota, live – jslm). This research was […]
Finance
Ascribe Bio Closes $12 Million Series A Financing to Advance Next-Generation Natural Crop Protection
Ascribe Bio, an innovator in natural crop protection, announced the closing of an oversubscribed $12 million Series A financing round, co-led by Corteva, through its Corteva Catalyst platform, and Acre Venture Partners. The financing also included participation […]
Finance
Seres Therapeutics Receives Award of up to $3.6M from Carb-X to Develop Liquid Formulation of Ser-155
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, announced that CARB-X, a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, will provide up to $3.6 million in additional non-dilutive funding to […]
Pharma & Human Health
Concerto Biosciences Announces Positive Topline Results from Phase 1b Clinical Trial of ENS-002 in Patients with Atopic Dermatitis
Concerto Biosciences®, a clinical-stage biotech company developing microbial products for therapeutics and consumer markets, today announced positive topline results from its first-in-human Phase 1b clinical trial evaluating ENS-002, a topical three-strain live biotherapeutic product for […]
Pharma & Human Health
Scientists develop a way to track donor bacteria after fecal microbiota transplants
Researchers at the Icahn School of Medicine at Mount Sinai and their collaborators have developed a new technology to track beneficial bacteria after fecal microbiota transplants (FMT). The approach provides a detailed view of how […]
Pharma & Human Health
Discovery of hundreds of new human gut viruses provides a new approach to studying the gut microbiome
Hundreds of new viruses living inside bacteria within our gut have been discovered in an international study led by Professor Jeremy J. Barr from Monash University’s School of Biological Sciences and Associate Professor Sam Forster […]
